M. Lawler

Evaluation of Gene Set Enrichment Analysis (GSEA) tools highlights the value of single sample approaches over pairwise for robust biological discovery.

This study compares GSEA tools and finds single sample approaches better capture biological distinctions than pairwise methods in cancer recurrence analysis.

MmCMS: Mouse models' Consensus Molecular Subtypes of colorectal cancer

The paper develops three methods to classify mouse colorectal cancer models into human CMS subtypes, finding that pathway-level classifiers outperform gene-level ones for accurate subtype identification.

Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data

The paper shows that transcriptional signatures in tumour samples can be misinterpreted due to stromal influences, affecting alignment with preclinical data.

An atlas of inter- and intra-tumor heterogeneityof apoptosis competency in colorectal cancertissue at single cell resolution

The paper generates an atlas of apoptosis susceptibility heterogeneity in colorectal cancer using single-cell analysis and ODE modeling, identifying intrinsic cellular differences in apoptosis competency.

Stratification Of Chemotherapy-Treated Stage III Colorectal Cancer Patients Using Multiplexed Imaging And Single Cell Analysis Of T Cell Populations

This study uses multiplexed imaging and single-cell analysis to classify immune cells in stage III colorectal cancer patients, finding that multi-marker Treg classification better predicts survival than single markers.

Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer

This study shows tolinapant, an IAP inhibitor, enhances chemotherapy-induced apoptosis in colorectal cancer by modulating FLIP and HDACs, suggesting its clinical use in poor prognosis MSS CRC with elevated cIAP1/2.

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer

The paper identifies Bcl-xL as a prognostic biomarker and predictor of response to adjuvant chemotherapy in BRAF-mutant stage II/III colon cancer using gene expression and immunohistochemistry validation.